Leveraging Real-World Evidence in a Rare Disease Oncology Drug Approval

August 13, 2020

Parexel experts discuss a recent project involving a Rare Disease Oncology therapeutic, in which our experts leveraged Real-World Evidence and FDA/Regulatory expertise to develop and execute a Synthetic Control Arm approach.

Previous Video
Innovation: Today’s patients, tomorrow’s medicines.
Innovation: Today’s patients, tomorrow’s medicines.

Sy Pretorius, EVP and Chief Medical & Scientific Officer, Parexel and Gadi Saarony, CEO, Advarra discuss h...

Next Video
Parexel Patient Advisory Council: EU Meeting
Parexel Patient Advisory Council: EU Meeting